Shinkichi Takamori
Shinkichi Takamori is an expert in Oncology at Dana-Farber Cancer Institute (United States). As of October 2026, ScienceLeadR ranks Shinkichi Takamori in the top 1% of experts worldwide for Bronchial Neoplasms, Lung Neoplasms and Thoracic Neoplasms. Shinkichi Takamori has authored 230 publications, the most recent in 2026. SLR score: 704 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Surgery - Pulmonology - Thoracic And Cardiovascular Surgery
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2016 - 2026
Number : 230
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| ASO Author Reflections: Rethinking Adjuvant Chemotherapy in Resected ALK-Positive Lung Cancer. PMID 42895674 — lung, neoplasms, drug therapy, lung neoplasms, chemotherapy, adjuvant, chemotherapy | Ann Surg Oncol | 2026 | 0 |
| Limited Impact of Adjuvant Chemotherapy in ALK-Positive Stage II-III Lung Adenocarcinoma: A Multicenter CReGYT-03 ALK Study. PMID 42832145 — lung, adenocarcinoma, carcinoma, non-small-cell lung, adenocarcinoma of lung, drug therapy, chemotherapy, adjuvant, therapeutics, chemotherapy | Ann Surg Oncol | 2026 | 0 |
| Perioperative Outcomes and Pathological Response After Neoadjuvant Nivolumab Plus Platinum Chemotherapy in Clinically Node-Negative Non-Small Cell Lung Cancer. PMID 42734698 — cells, lung, neoplasms, disease progression, carcinoma, non-small-cell lung, drug therapy, lung neoplasms, small cell lung carcinoma, nivolumab, therapeutics, chemotherapy | Ann Surg Oncol | 2026 | 1 |
| Perioperative Rehabilitation and Initiation of Adjuvant Chemotherapy in Resected Non-Small Cell Lung Cancer. PMID 42723143 — cells, lung, neoplasms, carcinoma, non-small-cell lung, rehabilitation, drug therapy, lung neoplasms, chemotherapy, adjuvant, small cell lung carcinoma, chemotherapy | Int J Cancer | 2026 | 0 |
| Oncological Outcomes of Segmentectomy for Centrally Located Small-Sized Non-small-cell Lung Cancer: A Multicenter Study (CReGYT-02 Study). PMID 42576113 — cells, confidence intervals, lung, probability, neoplasms, carcinoma, non-small-cell lung, mastectomy, segmental, lung neoplasms, small cell lung carcinoma, diagnosis, therapeutics | Ann Surg Oncol | 2026 | 0 |
LeadR Networks
Main global connection map